Tempest CAR-T Data Bolsters Dual-Targeting Approach in Myeloma
Event summary
- Tempest Therapeutics will present updated clinical data from the REDEEM-1 Phase 1/2a trial for its dual-targeting CD19/BCMA CAR-T therapy, TPST-2003, at the ISCT Annual Meeting on May 6-9, 2026.
- Interim data previously announced showed a 100% complete response rate among six evaluable patients.
- REDEEM-1 is a multicenter trial enrolling 29 patients in China, sponsored and conducted by Novatim.
- Tempest has exclusive rights to TPST-2003 outside of China, India, Turkey, and Russia.
The big picture
Tempest’s focus on dual-targeting CAR-T therapies aims to address antigen escape and improve response durability in relapsed/refractory multiple myeloma, a market with significant unmet need and intense competition. The REDEEM-1 data represents a potentially significant step forward, but the therapy’s commercial viability hinges on replicating these early results in a larger trial and securing regulatory approval. The partnership with Novatim introduces geographic and operational dependencies that investors should monitor closely.
What we're watching
- Clinical Validation
- The full REDEEM-1 trial results will be critical to assess whether the initial 100% complete response rate can be replicated across the entire patient cohort, influencing the therapy’s potential for regulatory approval.
- Partner Dynamics
- Novatim's execution of the REDEEM-1 trial and other ongoing studies will be key, as Tempest’s commercial prospects outside of China are contingent on Novatim’s performance.
- Competitive Landscape
- The success of TPST-2003 will be weighed against the progress of other dual-targeting CAR-T therapies in development, particularly given the crowded field and increasing scrutiny of CAR-T safety and efficacy.
Related topics